Sponsor Check › Person
Related person on Form D filings · address states as listed: CA, CO, NJ, MA, NM, L3 · listed Nov 24, 2009 → Mar 13, 2023
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: not yet · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
Not yet searched.
Sources to be searched: CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
Search queued. Results are added automatically; check back later or follow this page to be notified.
Not yet searched.
Sources to be searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
4 of 41 offerings report sales commissions totalling $1,996,599; 0 report finder's fees; 2 report proceeds to related persons totalling $173,000. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Mar 13, 2023 D File 021-475708 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 30, 2021 D File 021-404810 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 19, 2021 D File 021-392928 | $389,999 | $0 | $0 | Maxim Group LLC BrokerCheck CRD 120708 ↗ |
| EDGAR ↗ | Nov 29, 2017 D File 021-299736 | $400,000 | $0 | $0 | NONE no CRD number reported via Raymond James & Associates, Inc. (CRD 705 ↗) NONE no CRD number reported via Ladenburg Thalmann & Co. Inc. (CRD 505 ↗) |
| EDGAR ↗ | Sep 28, 2015 D File 021-248311 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 13, 2015 D/A File 021-241558 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 8, 2015 D File 021-239513 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 3, 2015 D File 021-233381 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 2, 2014 D File 021-225706 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 10, 2014 D/A File 021-211908 | $798,600 (est.) | $0 | $0 (est.) | Aegis Capital Corp. BrokerCheck CRD 15007 ↗ Kingsbury Capital LLC BrokerCheck CRD 147102 ↗ |
| EDGAR ↗ | Apr 23, 2014 D File 021-216115 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 12, 2014 D File 021-213450 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Feb 10, 2014 D File 021-211595 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 20, 2013 D File 021-208520 | $0 | $0 | $100,000 (est.) | None listed on this filing |
| EDGAR ↗ | Aug 20, 2013 D File 021-201639 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 9, 2013 D File 021-199233 | $0 | $0 | $73,000 (est.) | None listed on this filing |
| EDGAR ↗ | Dec 21, 2012 D/A File 021-171111 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 25, 2012 D File 021-184613 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 10, 2012 D File 021-182570 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 24, 2012 D/A File 021-43952 | $0 | $0 | $0 (est.) Certain persons named in Item 3 or affiliate(s) thereof may receive payments deemed to be made from the proceeds of the offering, including director fees and/or executive officer salaries. The amounts of such payments cannot be estimated at this time. | None listed on this filing |
| EDGAR ↗ | Jan 31, 2012 D File 021-172717 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 4, 2011 D/A File 021-163699 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 28, 2011 D File 021-167970 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 8, 2011 D File 021-164058 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 1, 2011 D File 021-163739 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 22, 2011 D File 021-163349 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 20, 2011 D File 021-163239 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 10, 2011 D/A File 021-141981 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Apr 13, 2011 D File 021-158280 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 7, 2011 D File 021-153226 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 13, 2010 D/A File 021-149968 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 3, 2010 D File 021-149969 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 19, 2010 D File 021-149305 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 19, 2010 D File 021-149306 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 12, 2010 D File 021-148861 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 12, 2010 D File 021-148863 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 27, 2010 D File 021-141176 | $0 | $0 | $0 (est.) The Issuer will pay HCV Management IX LLC, its Management Company, an annual management fee equal to a percentage of its committed capital or capital under management. | None listed on this filing |
| EDGAR ↗ | Feb 3, 2010 D/A File 021-56316 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Jan 19, 2010 D File 021-55322 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 24, 2009 D File 021-115615 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Dec 8, 2008 D File 021-60286 | $408,000 | $0 | $0 | Seaview Securities LLC BrokerCheck CRD 126180 ↗ |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | LEAP THERAPEUTICS, INC. | Executive Officer Mr. Lawlor is the Chief Operating Officer of the Issuer. | Mar 13, 2023 | D | $77,219,193 similar: $1,694,259–$16,000,000 | $77,219,193 | 121 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | LayerBio, Inc. | Director | Jun 30, 2021 | D | $1,000,000 similar: $2,000,000–$19,999,994 | $50,000 | 2 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | PAINREFORM LTD. | Director | Mar 19, 2021 | D | $6,000,000 similar: $2,000,000–$19,999,994 | $6,000,000 | 3 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | LEAP THERAPEUTICS, INC. | Executive Officer Chief Operating Officer | Nov 29, 2017 | D | $18,000,001 similar: $2,000,000–$19,999,994 | $18,000,001 | 14 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | VAXINNATE CORP | Director | Sep 28, 2015 | D | $4,341,507 similar: $2,000,000–$19,999,994 | $3,248,047 | 14 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | CATALYST BIOSCIENCES INC | Director | Jul 13, 2015 | D/A | $2,000,000 similar: $2,000,000–$19,999,994 | $1,890,938 | 10 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | CATALYST BIOSCIENCES INC | Director | Jun 11, 2015 | D | $1,000,000 similar: $2,000,000–$19,999,994 | $1,000,000 | 10 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | GITR Inc. | Executive Officer, Director The President of the Issuer. | May 8, 2015 | D | $18,500,000 similar: $2,000,000–$19,999,994 | $1,500,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | CATALYST BIOSCIENCES INC | Director | Feb 3, 2015 | D | $5,000,000 similar: $2,000,000–$19,999,994 | $3,224,993 | 11 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | VAXINNATE CORP | Director | Oct 2, 2014 | D | $6,265,125 similar: $2,000,000–$19,999,994 | $6,000,000 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | GLOBEIMMUNE INC | Director | Jun 10, 2014 | D/A | $7,500,000 similar: $1,694,259–$16,000,000 | $7,500,000 | 110 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | CATALYST BIOSCIENCES INC | Director | Apr 23, 2014 | D | $5,009,841 similar: $2,000,000–$19,999,994 | $5,009,841 | 18 similar: 2–16 | $3,000 similar: $10,000–$50,000 |
| EDGAR ↗ | GLOBEIMMUNE INC | Director | Mar 12, 2014 | D | $391,730 similar: $1,694,259–$16,000,000 | $391,730 | 1 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | GLOBEIMMUNE INC | Director | Feb 13, 2014 | D | $7,500,000 similar: $1,694,259–$16,000,000 | $7,500,000 | 92 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Mosaic Biosciences, Inc. | Director | Feb 10, 2014 | D | $2,310,000 similar: $2,000,000–$19,999,994 | $2,274,000 | 4 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | NANOMR, INC. | Director | Dec 20, 2013 | D | $2,400,000 similar: $2,000,000–$19,999,994 | $2,400,000 | 3 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | CATALYST BIOSCIENCES INC | Director | Aug 20, 2013 | D | $800,008 similar: $2,000,000–$19,999,994 | $400,004 | 11 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | NANOMR, INC. | Director | Jul 9, 2013 | D | $2,623,512 similar: $2,000,000–$19,999,994 | $2,623,512 | 3 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | GITR Inc. | Executive Officer, Director | Dec 21, 2012 | D/A | $6,500,000 similar: $1,694,259–$16,000,000 | $3,250,000 | 1 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | CATALYST BIOSCIENCES INC | Director | Sep 25, 2012 | D | $18,593,361 similar: $2,000,000–$19,999,994 | $13,407,658 | 21 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Stemgent, Inc. | Director | Aug 10, 2012 | D | $11,299,993 similar: $2,000,000–$19,999,994 | $11,299,993 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | GITR Inc. | Executive Officer, Director | Jun 12, 2012 | D/A | $2,750,000 similar: $1,694,259–$16,000,000 | $2,250,000 | 1 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | VAXINNATE CORP | Director | Feb 24, 2012 | D/A | $24,969,925 similar: $2,000,000–$19,999,994 | $24,810,408 | 13 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Stemgent, Inc. | Director | Jan 31, 2012 | D | $8,797,992 similar: $2,000,000–$19,999,994 | $6,297,998 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | GITR Inc. | Executive Officer, Director | Jan 4, 2012 | D | $2,000,000 similar: $1,694,259–$16,000,000 | $1,250,000 | 1 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Pathogenetix, Inc. | Director | Nov 4, 2011 | D/A | $11,500,000 similar: $2,000,000–$19,999,994 | $11,499,996 | 5 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Stemgent, Inc. | Director | Oct 28, 2011 | D | $600,000 similar: $2,000,000–$19,999,994 | $584,810 | 6 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Tensha Therapeutics, Inc. | Director | Aug 8, 2011 | D | $15,000,000 similar: $1,694,259–$16,000,000 | $500,000 | 2 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Apofore Corp | Director | Aug 1, 2011 | D | $10,000,000 similar: $1,694,259–$16,000,000 | $500,000 | 2 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Pathogenetix, Inc. | Director | Jul 29, 2011 | D | $9,500,000 similar: $2,000,000–$19,999,994 | $3,999,996 | 5 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | NANOMR, INC. | Director | Jul 22, 2011 | D | $17,930,685 similar: $2,000,000–$19,999,994 | $11,430,685 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Mosaic Biosciences, Inc. | Director | Jul 20, 2011 | D | $1,030,462 similar: $2,000,000–$19,999,994 | $1,030,462 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Stemgent, Inc. | Director | Jun 10, 2011 | D/A | $14,127,591 similar: $2,000,000–$19,999,994 | $10,627,591 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Stemgent, Inc. | Director | Apr 13, 2011 | D | $3,000,000 similar: $2,000,000–$19,999,994 | $750,000 | 8 similar: 2–16 | $3,451 similar: $10,000–$50,000 |
| EDGAR ↗ | VAXINNATE CORP | Director | Apr 8, 2011 | D/A | $21,927,703 similar: $2,000,000–$19,999,994 | $21,698,759 | 12 similar: 2–16 | $544 similar: $10,000–$50,000 |
| EDGAR ↗ | VAXINNATE CORP | Director | Feb 15, 2011 | D/A | $16,857,334 similar: $2,000,000–$19,999,994 | $16,679,752 | 12 similar: 2–16 | $544 similar: $10,000–$50,000 |
| EDGAR ↗ | LEAP THERAPEUTICS, INC. | Director | Jan 7, 2011 | D | $30,500,000 similar: $1,694,259–$16,000,000 | $9,930,400 | 4 similar: 1–13 | $2,930,400 similar: $10,000–$55,000 |
| EDGAR ↗ | Pathogenetix, Inc. | Director | Dec 13, 2010 | D/A | $1,810,453 similar: $2,000,000–$19,999,994 | $1,510,453 | 5 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Pathogenetix, Inc. | Director | Nov 3, 2010 | D | $1,200,000 similar: $2,000,000–$19,999,994 | $900,000 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Pathogenetix, Inc. | Director | Nov 3, 2010 | D | $1,310,453 similar: $2,000,000–$19,999,994 | $1,310,453 | 4 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Anexon, Inc. | Director | Oct 19, 2010 | D | $2,000,000 similar: $2,000,000–$19,999,994 | $2,000,000 | 2 similar: 2–16 | $250,000 similar: $10,000–$50,000 |
| EDGAR ↗ | Anexon, Inc. | Director | Oct 19, 2010 | D | $3,000,000 similar: $2,000,000–$19,999,994 | $3,000,000 | 2 similar: 2–16 | $83,333 similar: $10,000–$50,000 |
| EDGAR ↗ | Shape Pharmaceuticals, Inc. | Director | Oct 12, 2010 | D | $4,500,000 similar: $1,694,259–$16,000,000 | $1,000,000 | 1 similar: 1–13 | $400,000 similar: $10,000–$55,000 |
| EDGAR ↗ | Shape Pharmaceuticals, Inc. | Director | Oct 12, 2010 | D | $2,000,000 similar: $1,694,259–$16,000,000 | $2,000,000 | 1 similar: 1–13 | $2,000,000 similar: $10,000–$55,000 |
| EDGAR ↗ | Stemgent, Inc. | Director | May 13, 2010 | D | $10,127,600 similar: $2,000,000–$19,999,994 | $5,627,599 | 6 similar: 2–16 | $500,000 similar: $10,000–$50,000 |
| EDGAR ↗ | HealthCare Ventures IX, L.P. | Director | Apr 27, 2010 | D | $250,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | $50,000 similar: $1,000–$100,000 |
| EDGAR ↗ | VAXINNATE CORP | Director | Mar 19, 2010 | D | $15,623,377 similar: $2,000,000–$19,999,994 | $5,207,792 | 12 similar: 2–16 | $2,835 similar: $10,000–$50,000 |
| EDGAR ↗ | GLOBEIMMUNE INC | Director | Feb 3, 2010 | D/A | $17,999,124 similar: $1,694,259–$16,000,000 | $17,999,124 | 27 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | GLOBEIMMUNE INC | Director | Jan 27, 2010 | D | $17,999,124 similar: $1,694,259–$16,000,000 | $17,507,816 | 26 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Pathogenetix, Inc. | Director | Jan 19, 2010 | D | $2,000,000 similar: $2,000,000–$19,999,994 | $1,000,000 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Stemgent, Inc. | Director | Nov 24, 2009 | D | $3,000,000 similar: $500,000–$7,000,000 | $2,700,000 | 2 similar: 2–14 | $10,000 similar: $5,000–$50,000 |
| EDGAR ↗ | GLOBEIMMUNE INC | Director | May 20, 2009 | D | $13,000,000 similar: $1,694,259–$16,000,000 | $13,000,000 | 1 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | VAXINNATE CORP | Director | May 19, 2009 | D | $31,000,000 similar: $2,000,000–$19,999,994 | $15,000,000 | 12 similar: 2–16 | $3,558 similar: $10,000–$50,000 |
| EDGAR ↗ | GLOBEIMMUNE INC | Director | Mar 17, 2009 | D | $5,000,000 similar: $1,694,259–$16,000,000 | $2,564,710 | 17 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | CATALYST BIOSCIENCES INC | Director | Dec 8, 2008 | D | $40,399,998 similar: $2,000,000–$19,999,994 | $40,399,998 | 10 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); Biotechnology / 506(b) (3,253 filings); Pooled Investment Fund / 506(b) (83,801 filings); Other / 506(b) (18,678 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Not linked to this profile — a second identifier (same issuer, same sponsor group) was not found. Could be the same person or a different one.
People and management entities the issuers listed as related persons on the same Form D filings as Augustine Lawlor. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Augustine Lawlor appears on a new Form D, or when a court case or SEC action is matched to them. See plans →